Green Cross Health Ltd · NZX:GXH
Green Cross Health — Shareholder Meeting (August 2024)
26 slides from Green Cross Health's shareholder meeting presentation, Aug 1, 2024
Slide 1: Annual Shareholders' Meeting
A nn u a l S ha r e h ol d e r s ’ M e e ti n g 1 August 2024 1
Slide 2: Agenda
Agenda • Chair’s address • Group CEO’s address • Voting on resolutions • General Q&A GXH Annual Shareholders' Presentation 1 August 2024 2
Slide 3: Rachael Newfield, Group CEO
Rachael Newfield Group CEO GXH Annual Shareholders' Presentation 1 August 2024 3
Slide 4: Milestones
Milestones Enrolled Patients Acquired Woodham Road Medical and Free Co-payment Acquisitions Papakura East After years of sector Acquisition Invested in Medical; the Medical lobbying, funders Division now Acquired Richmond Tarawera Medical introduce free exceeds 400,000 Road Medical Centre and Onerah
Slide 5: GXH Annual Result – Financial Overview
GXH Annual Result – Financial Overview $$$$ Group Operating Profit Net Profit After Tax* Revenue* (EBIT)* (attributable to shareholders) $503.9m $31.8m $12.0m 2% increase vs FY23 7% decrease vs FY23 20% decrease vs FY23 *continuing operations *continuing operations *continuing operations Pharmacy Me
Slide 6: Group Revenue and Operating Profit
Group Revenue and Operating Profit GXH GXHOperating OperatingRevenue RevenueFrom FromContinuing ContinuingOperations ($m) GXH Operating Profit From Continuing Operations ($m) Operations ($m) 478 494 504 399 48.5 31.4 34.3 31.8 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 • Revenue of $504m, up 2% • Opera
Slide 7: Group NPAT, EPS & Dividend
Group NPAT, EPS & Dividend GXH NPAT Attributable to Shareholders* ($m) Dividends Per Share (cps) 20.2 34.0 13.4 15.0 12.0 6.5 7.0 0.0 FY21 FY22 FY23 FY24 FY21 FY21 FY22 FY23 FY24 Based on dividends declared during the financial year GXH NPAT Attributable to Shareholders* (cps) • EPS at 8.4 cps* • Sp
Slide 8: Working Capital Management Disciplines Supporting Further Acquisition Activity
Working Capital Management Disciplines Supporting Further Acquisition Activity Gearing Ratio (debt / debt + equity) GXH Operating Cash Flow ($m) 17.3% 70.9 65.8 14.0% 12.3% 45.9 46.0 10.4% FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 • Gearing ratio of 17.3% in FY24 • Operating Cash Flow of $46.0m • Undr
Slide 9: Divisional Performance & Plans
Divisional Performance & Plans GXH Annual Shareholders' Presentation 1 August 2024 9
Slide 10: Who We Are
Who We Are Our Purpose: Working together to support healthier communities. We are passionately committed to the health and wellness of New Zealand, and to providing the best support, care and advice to our communities. This is our promise. GXH Annual Shareholders' Presentation 1 August 2024 10
Slide 11: Pharmacy Performance
Pharmacy Performance Pharmacy Operating Revenue ($m) 367.1 360.4 363.6 316.8 FY21 FY22 FY23 FY24 • Revenue up 1% to $363.6m FY21 FY22 FY23 FY24 • Operating Profit down $1.8m to $19.3m due to labour Pharmacy Operating Profit ($m) cost pressures and inflation impacting margins • Initial scripts items
Slide 12: Continued Growth in Vaccination Income
Continued Growth in Vaccination Income Tot a l Vac Total c i n a ti o n s Vaccinations - G r ee - Green n CrHealth Cross o ss He al th NeNetwork t w o r k ( (‘000) ‘ 00 0 ) 324 294 FY23 FY23 FY24 FY24 Following record numbers last year, flu vaccinations continued to grow (5% increase year-on-year),
Slide 13: Continued Growth in Living Rewards Members
Living Rewards Programme 2.03m Living Rewards Members Spend More Continued ContinuedGrowth GrowthininLiving LivingRewards RewardsMembers Members $60 (millions) Members (millions) $ spend per transaction $50 $40 $30 1.95 2.03 $20 1.81 1.89 $10 $0 Unichem Life Total FY21 FY21 FY22 FY22 FY23 FY23 FY24
Slide 14: Pharmacy Future Focus
Pharmacy Future Focus Brand & Retail Omni-channel Network scale & Cost focus customer disciplines experience leadership Differentiated brands Professional instore Care & advice Leveraging our trusted Workforce and products & experience & margin accessible to the brands & advocating for productivity
Slide 15: Medical Performance
Medical Performance Medical Operating Revenue ($m) 133.2 140.3 111.0 82.2 Revenue up 5% to $140.3m FY21 FY21 FY22 FY22 FY23 FY23 FY24 FY24 Operating Profit down $1.2m to $15.0m, with labour cost pressures and reduced COVID-19 Medical Operating Profit ($m) services impacting margin 423,000 enrolled p
Slide 16: Growth through Acquisitions
Growth through Acquisitions Medical Acquisitions • Continued acquisition activity with investment in seven centres in year, to close with 66 medical centres 9 8 7 • The Doctors has New Zealand’s largest general practice 3 enrolled patient base FY21 FY21 FY22 FY22 FY23 FY23 FY24 FY24 • One additional
Slide 17: Investment in Practice Portfolio
Investment in Practice Portfolio Centre Refurbishments 3 3 3 1 FY21 FY21 FY22 FY22 FY23 FY23 FY24 FY24 • Three significant refurbishments completed (Ti Rakau, Hastings, Te Whare Hapara) to enhance patient environment and the delivery of patient care • Rebrand programme continued with 44 centres now
Slide 18: Medical Future Focus
Medical Future Focus Patient & Brand Scale Technology Operations Cost & improvement margin High quality patient Targeted centre Utilising data and Continuous Workforce care acquisitions systems & omni- improvement & clinical productivity & channel offering development margin management GXH Annual Sh
Slide 19: Q&A
Q&A GXH Annual Shareholders' Presentation 1 August 2024 19
Slide 20: Resolutions & Voting
Resolutions & Voting GXH Annual Shareholders' Presentation 1 August 2024 20
Slide 21: Resolutions
Resolutions Resolution 1: Re-election of Peter Merton Resolution 2: Re-election of Ken Orr Resolution 3: Remuneration of the Auditor GXH Annual Shareholders' Presentation 1 August 2024 21
Slide 22: Re-election of Peter Merton
Resolution 1 Re-election of Peter Merton Peter Merton to be re-elected as Director of the Company GXH Annual Shareholders' Presentation 1 August 2024 22
Slide 23: Re-election of Ken Orr
Resolution 2 Re-election of Ken Orr Ken Orr to be re-elected as Director of the Company GXH Annual Shareholders' Presentation 1 August 2024 23
Slide 24: Remuneration of the Auditor
Resolution 3 Remuneration of the Auditor To authorise the Directors to fix the remuneration of the Auditor for the ensuing year GXH Annual Shareholders' Presentation 1 August 2024 24
Slide 25: Q&A
Q&A GXH Annual Shareholders' Presentation 1 August 2024 25
Slide 26: Disclaimer
Disclaimer The information in this presentation was prepared by Green Cross Health Limited (GXH) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability
Green Cross Health — Shareholder Meeting (August 2024) on 6ix